In this episode, we discuss the art of caring for terminally ill patients with Dr. Azra Raza. We also discuss her book titled "The First Cell", where she recounts numerous poignant stories of her patients with terminal cancer, and teaches us how to find hope amidst despair. Link to the book: https://www.amazon.com/First-Cell-Human-Pursuing-Cancer/dp/1541699521
In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser. Here are the shownotes: 1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma: https://x.com/Rfonsi1/status/1206004966294294528?s=20 2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs: https://pubmed.ncbi.nlm.nih.gov/28655925/ 3...
In this episode, we discuss the management of primary CNS lymphoma, secondary CNS lymphoma and CNS prophylaxis with Dr. Kate Cwynarski. Here are the shownotes: 1. ASH 2022 data on PET scan in CNS lymphoma - https://ashpublications.org/blood/article/140/Supplement%201/1334/492207/Is-It-Possible-to-Omit-Bone-Marrow-Biopsy-in?searchresult=1 2. Elizabeth Schorb ASH 2022 (MARTA) 65-80 year olds – https://ashpublications.org/blood/article/140/Supplement%201/1773/493224/High-Dose-Chemotherapy-and-Autol...
In this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies. Here are the key studies that we touched upon: 1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and PCL: https://pubmed.ncbi.nlm.nih.gov/37315268/ 2. Meta-analysis of >2500 patients with chromosome 1q21 abnormalities : https://pubmed.ncbi.nlm.nih.gov/34092058/ 3. Predicting ultra-high risk myeloma by molecul...
In this episode, we discuss the diagnosis and management of peripheral T-cell lymphoma with Dr. Steven Horwitz, with a focus on the 3 most common types-Peripheral T-cell Lymphoma-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), and Anaplastic Large Cell Lymphoma (ALCL). Here are the key papers we discussed: 1. “ How I Treat Peripheral T-cell Lymphoma? ”: https://pubmed.ncbi.nlm.nih.gov/24615779/ 2. ECHELON-2- RCT of CHOP vs BV-CHP in CD30-positive peripheral T-cell lymphomas: https://pubmed.ncbi....
In this episode, we discuss the diagnosis and management/monitoring of Clonal Cytopenias of Unknown Significance (CCUS) with Dr. Uma Borate. We also discuss the emerging data on risk stratification and key trials in this space that are currently ongoing. Here are the shownotes: 1. CCUS and risk of transformation to myeloid neoplasms: https://www.sciencedirect.com/science/article/pii/S0006497121013471 2. Prediction of risk for myeloid neoplasms in clonal hematopoiesis: https://evidence.nejm.org/d...
In this episode, we delve into the diagnosis and management of Paroxysmal Nocturnal Hemoglobinuria (PNH) with Dr. Robert Brodsky. Here are the shownotes for key papers we discussed in the episode: How I treat PNH : https://pubmed.ncbi.nlm.nih.gov/33512400/ Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia : https://pubmed.ncbi.nlm.nih.gov/37084383/ Pegcetacoplan versus eculizumab in PNH : a) https://pubmed.ncbi.nlm.nih.gov/33730455/...
In this episode, we delve into the history of frontline treatment in young/fit patients with Hodgkin's lymphoma and recent developments in the past decade with Dr. Nancy Bartlett from Washington University. Link for our Blood Cancer Talks Survey: https://bit.ly/BCTS Here are the key trials we discussed: 1. RATHL Trial (PET-adapted treatment of Advanced Hodgkin’s Lymphoma): https://pubmed.ncbi.nlm.nih.gov/27332902/ 2. S0816 (PET-adapted treatment of Advanced Hodgkin’s Lymphoma): https://pubmed.nc...
In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center. Here are some of the key articles we discussed: 1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”. https://pubmed.ncbi.nlm.nih.gov/36989488/ 2. CAR-HEMATOTOX score: https://pubmed.ncbi.nlm.nih.gov/34166502/ 3. “How I treat cytopenias after CAR T-cell therapy”. https://pubmed.ncbi.nlm.nih.gov/36800563/ 4. Immune Effe...
In this episode, we discuss the latest updates on CAR T-cell therapy in multiple myeloma, including the studies presented at ASCO and EHA 2023. Here are the show notes: 1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf9 2. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma: a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/ b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi...
In this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed: 1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/ 2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/487619 3. Talquetamab (MonumenTAL-1 trial): https://pubmed.ncbi.nlm.nih.gov/36507686/ 4. Phase 1 trial of fixed-duration cevostamab : https://ashpublications.org/...
In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA". Here are the key studies discussed: 1. ASH choosing wisely: https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely 2. International Consensus Classification (ICC): https://pubmed.ncbi.nlm.nih.g...
In this episode, we delve into the management of newly diagnosed mantle cell lymphoma with Dr. Martin Dreyling. Here the shownotes: 2:11 How to diagnose mantle cell lymphoma (MCL)? 6:51 Clinical manifestations of mantle cell lymphoma 7:52 How to manage leukemic variant of MCL? 12:08 Is Watch-and-Wait reasonable in selected cases of nodal MCL with low Ki-67? 17:21 Overview on treatment of newly diagnosed MCL 19:03 Are all cytarabine-based regimens for MCL created equally? RCT of Autologous Transp...
In this episode, we discuss the management of multiple myeloma in LMICs with Dr. Andrés Gómez-De León from UANL, Monterrey, Mexico, and Dr. Aditya Jandial from PGIMER, Chandigarh, India. This episode was inspired by an article in Lancet Haematology titled “ The Underrepresented Majority ”, which highlighted the lack of access to some of the basic anti-myeloma drugs in LMICs and the resulting disparity in global outcomes. Here are some of the sections discussed in this episode: 03:33 Diagnostic w...
In this episode, we discuss the diagnosis and management of primary myelofibrosis with Dr. Ayalew Tefferi at Mayo Clinic, Rochester, Minnesota. Here are the show notes, including key studies discussed in this episode: 1. Risk stratification of PMF : MIPSS70 Score : http://www.mipss70score.it https://ascopubs.org/doi/full/10.1200/JCO.2017.76.4886 Genetically inspired prognostic scoring system (GIPSS) : https://www.nature.com/articles/s41375-018-0107-z Type 1 CALR mutation : https://ashpublication...
1. How I Approach Smoldering Myeloma (Vaxman and Gertz): https://ashpublications.org/blood/article/140/8/828/485274 2. Risk-Stratification Models in SMM: Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/ PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/ PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/ IMWG SMM model: https://pubmed.ncbi.nlm.nih.gov/33067414/ 3. QuiRedex RCT (Lenalidomide-Dexamethasone vs Observation in High-Risk SMM): https://pubmed.ncbi.nlm.nih....
In this episode, we discuss the management of acquired aplastic anemia with Dr. Amy DeZern. Here are the links to some of the key articles discussed in this show: 1. Review article on aplastic anemia: https://www.nejm.org/doi/10.1056/NEJMra1413485 2. RCTs testing whether addition of cyclosporine to ATG improves outcomes in aplastic anemia: https://www.nejm.org/doi/10.1056/NEJM199105093241901 https://www.sciencedirect.com/science/article/pii/S0006497120489748 3. RCT testing horse versus rabbit AT...
1. Phase III ASAP trial https://ash.confex.com/ash/2022/webprogram/Paper159962.html 2. Phase III Dauno-Double Trial https://ash.confex.com/ash/2022/webprogram/Paper157126.html 3. Reduced venetoclax exposure : https://ash.confex.com/ash/2022/webprogram/Paper165464.html 4 . Menin Inhibitors in AML https://ash.confex.com/ash/2022/webprogram/Paper164849.html https://ash.confex.com/ash/2022/webprogram/Paper167412.html 5 . Imetelstat in MDS: IMerge Phase 2 https://ash.confex.com/ash/2022/webprogram/Pa...
In this episode, we discuss the management of newly diagnosed DLBCL with Dr. Pallawi Torka. We also have a few bonus ASH22 updates on DLBCL. Links to articles and abstracts discussed in the episode are as follows: 1. A comprehensive review article on DLBCL: https://pubmed.ncbi.nlm.nih.gov/33657296/ 2. RCT testing CHOP vs Three Intensive Regimens in DLBCL: https://www.nejm.org/doi/full/10.1056/nejm199304083281404 3. RCT testing R-CHOP vs CHOP in DLBCL in older adults: https://www.nejm.org/doi/ful...
1. Excellent paper on harmonization of performing and reporting MRD in multiple myeloma: https://www.nature.com/articles/s41375-020-01012-4 2. Does CR really matter in the era of MRD? Landmark paper from the Spanish Group: https://pubmed.ncbi.nlm.nih.gov/35560160/ 3. Meta-analysis showing individual-level prognostic impact of MRD on long-term outcomes in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/33284948/ 4. MASTER Trial-The first trial testing MRD-adapted treatment strategy in multiple ...
Study showing the time from diagnosis of AML to the start of intensive treatment indicate that a treatment delay has no negative prognostic impact. https://ashpublications.org/blood/article/136/7/823/460669/Does-time-from-diagnosis-to-treatment-affect-the RATIFY clinical trial showing the addition of midostaurin (FLT3 inhibitor) to 7+3 chemotherapy for AML https://www.nejm.org/doi/full/10.1056/nejmoa1614359 Diagnosis and management of AML in adults: 2022 recommendations from an international exp...
1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myeloma https://ash.confex.com/ash/2022/webprogram/Paper159606.html https://ash.confex.com/ash/2022/webprogram/Paper168930.html 2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model. https://ash.confex.com/ash/2022/webprogram/Paper170166.html Link to the model: https://istopmm.com/riskmodel/ 3. RCT comparing Rd (continuous) vs Rd in...
ALPINE Trial : Zanubrutinib vs Ibrutinib in Relapsed/Refractory CLL (https://www.nejm.org/doi/full/10.1056/NEJMoa2211582) CLL2-Give Trial: Updated results Obinutuzumab (G), Ibrutinib (I), and Venetoclax (Ve) triplet in Untreated Patients with CLL with 17p Deletion/TP53 Mutation (https://ash.confex.com/ash/2022/webprogram/Paper163245.html) AVO Trial : Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease (https://ash...
Excellent overview of Castleman Disease: https://ashpublications.org/blood/article/135/16/1353/452573/Overview-of-Castleman-disease International consensus guideline for treatment of Idiopathic Multicentric Castleman Disease (iMCD): https://ashpublications.org/blood/article/132/20/2115/39506/International-evidence-based-consensus-treatment Somatic alterations in Castleman Disease: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624446/ https://www.nature.com/articles/s41375-018-0323-6 Rituximab + ...
In this episode, we discussed the three CD19-directed chimeric antigen receptor (CAR T-cell) therapies that have been approved for relapsed/refractory aggressive large B cell lymphomas (LBCL) after two lines of therapy: Axicabtagene ciloleucel (axi-cel) https://www.nejm.org/doi/full/10.1056/nejmoa1707447 Tisagenlecleucel (tisa-cel) https://www.nejm.org/doi/full/10.1056/nejmoa1804980 Lisocabtagene maraleucel (lisocel) https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31366-0/full...
Key articles and trials discussed in the episode: 1. Excellent review in NEJM on treatment of CLL (2020): https://www.nejm.org/doi/full/10.1056/NEJMra1908213 2. Alliance Trial (Ibrutinib vs chemoimmunotherapy in older patients with untreated CLL): https://www.nejm.org/doi/full/10.1056/NEJMoa1812836 3. E1912 (Ibrutinib vs chemoimmunotherapy in younger/fit patients with CLL): https://www.nejm.org/doi/full/10.1056/NEJMoa1817073 4. RCT testing Acalabrutinib vs Ibrutinib (non-inferiority) in relapsed...
Key papers discussed in the show: 1. Pediatric regimen for older adolescents and young adults with ALL: CALGB 10403 https://ashpublications.org/blood/article/133/14/1548/260519/A-pediatric-regimen-for-older-adolescents-and 2. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: C19802 https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.27617 3. Rituximab in B-ALL https://www.nejm.org/doi/full/10.1056/NEJMoa1605085 4. A Phase II Tria...
Key papers discussed in the show: 1. Landmark paper on HLA-mismatch and survival: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568127/ 2. HLA-DP and Risk of GVHD: https://www.nejm.org/doi/full/10.1056/NEJMoa1500140 3. Outcomes of Allogeneic Transplant with HLA-Mismatched Unrelated Donor: https://ascopubs.org/doi/10.1200/JCO.20.03502 4. Review/perspective on fundamentals of unrelated donors and cord blood units: https://ashpublications.org/blood/article/120/2/259/30405/A-perspective-on-the-selec...
In this episode, we do a thought provoking discussion with Dr. Marty Tallman on mentorship and career development in academic hematology and medical oncology. A must listen for all trainees and early career clinical investigators. Sage wisdom from a legend in the field!
2021 European LeukemiaNET MRD Working Party Consensus Guidelines: https://pubmed.ncbi.nlm.nih.gov/34724563/ Pre-MEASURE Study ASCO 2022: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7006
